ArticleTranslational cancer research2025
Association between the age-adjusted visceral adiposity index (AVAI) and gynecologic malignancies: a cross-sectional study based on NHANES data.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obesityand Gynaecological Cancers, with a Focus on Morbid Obesity: Risk Stratification, Early Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gynecologic cancers pose a significant threat to women's health worldwide, with obesity and related metabolic dysfunction recognized as key risk factors. Traditional measures, such as body mass index (BMI), fail to adequately capture visceral fat, which plays a crucial role in tumorigenesis through metabolic and inflammatory pathways. This study aims to assess the association between the age-adjusted visceral adiposity index (AVAI) and the risk of gynecologic cancers using data from the National Health and Nutrition Examination Survey (NHANES). Methods: This study analyzed a cross-sectional dataset from the NHANES [2007-2018], comprising 7,855 women, including 237 with gynecologic cancers (ovarian, endometrial, and cervical cancers) and 7,618 control participants without cancer. The AVAI was the main exposure variable. To control for potential confounders, such as age, race, educational level, the poverty-to-income ratio (PIR), smoking status, alcohol intake, hypertension, diabetes, and the BMI, multivariable logistic regression and generalized additive models were employed. The independent link between the AVAI and the risk of gynecologic cancers was examined. Additionally, subgroup analyses and restricted cubic spline functions were used to assess dose-response trends, while receiver operating characteristic (ROC) curves were generated to evaluate the discriminative performance of the AVAI. Results: Women with gynecologic cancers were older (P=0.02) and had higher waist circumference (WC), BMI, triglyceride (TG), and AVAI levels (P<0.001) than those in the control group. In the fully adjusted model I, each unit increase in the AVAI was associated with a 28.0% higher risk of gynecologic malignancies [odds ratio (OR) =1.280, 95% confidence interval (CI): 1.089-1.504, P=0.003]. Subgroup analysis showed a significant association with cervical cancer: each unit increase in AVAI resulting in a 30.9% higher risk in model I (P=0.02) and a 45.6% higher risk in model II (P=0.03), revealing a dose-response trend [Q2 (-8.7292 to -6.3966) Conclusions: The AVAI, a composite index that integrates visceral fat distribution and metabolic function, was shown for the first time to be significantly associated with the risk of gynecologic malignancies, particularly cervical cancer, for which it demonstrated strong discriminative value. The study shows the superiority of the AVAI over traditional BMI in metabolic-inflammatory risk stratification, offering a new target for early identification and targeted interventions in gynecologic cancers. Future prospective cohort studies need to be conducted to verify causality and explore metabolic regulation strategies targeting the AVAI to reduce the risk of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.